TY - JOUR
T1 - Reviewing Dengue
T2 - Still a Neglected Tropical Disease?
AU - Horstick, Olaf
AU - Tozan, Yesim
AU - Wilder-Smith, Annelies
N1 - Funding Information:
While the 2013 World Health Assembly resolution on NTDs urged member states to take ownership of national programmes and international partners to provide sufficient and predictable funding streams for implementation, R&D of new tools, and technologies, it also highlighted the growing threat and spread of dengue in affected countries and beyond []. Dengue is not one of the ten NTDs prioritised in the 2012 London Declaration. Against a background of increasing ODA for health in general and national NTD programmes in particular, the financial support for dengue prevention and control programmes in endemic countries has been strictly limited to isolated outbreak response through emergency funds []. Dengue endemic countries rely primarily on their own national resources for dengue control and surveillance activities.
Funding Information:
The rapid geographical expansion of dengue [,] has been paralleled by an increase in dengue research and research funding. This increase was further spurred by the perceived threat of dengue to currently noninfected areas, including the threat to Western countries. Imported dengue cases via international travellers to Western countries are rising []. Another important factor that has led to more spending in dengue research is the fact that many of the currently dengue endemic countries have experienced rapid economic growth and emerged as new strong markets—on the other hand, this has also resulted in fewer grants from funding agencies orientated towards poorer countries. Dengue has also attracted the attention of novel actors in the field from both the academic and corporate world. The most active (i.e., having a significant number of dengue research projects funded in the last ten years) and large-scale funding agencies are the Bill and Melinda Gates Foundation, the National Institute of Health (United States of America), the Wellcome Trust (United Kingdom), and the European Union (EU), underlining the fact that the vast majority of funding dengue research centres receive remains in nondengue endemic countries, both at the academic and corporate level, with the notable exceptions of Brazil and Singapore. The European Commission (EC) has been supporting research programmes in infectious diseases since the 1990s. A total of 25 projects on dengue have been supported []. In 2010, the EC launched a call under the Seventh Framework Programme with the title of “Comprehensive control of dengue fever under changing climatic conditions” []. The EC awarded a total of approximately €18 million to three consortia [,]. The consortia comprise 38 partners from around the world.
Funding Information:
To combat NTDs, the Novartis Institute of Tropical Diseases (NITD) [] was founded in 2002 through private public funding from Novartis and the Singapore Economic Development Board. One of NITD's missions is to develop antivirals for dengue virus. The International Consortium on Antivirals (ICAV) is a not-for-profit drug development organisation whose mandate is also to discover and develop affordable antiviral therapies for NTDs []. ICAV operates through a network of collaborative laboratories and by liaising with governments and other stakeholders. The most recent large-scale funding on dengue antiviral drug discovery and design is from the FP7-SILVER project, which has dengue as one out of its three main targets for antivirals.
Publisher Copyright:
© 2015 Horstick et al.
PY - 2015/4/30
Y1 - 2015/4/30
N2 - Dengue is currently listed as a “neglected tropical disease” (NTD). But is dengue still an NTD or not? Classifying dengue as an NTD may carry advantages, but is it justified? This review considers the criteria for the definition of an NTD, the current diverse lists of NTDs by different stakeholders, and the commonalities and differences of dengue with other NTDs. We also review the current research gaps and research activities and the adequacy of funding for dengue research and development (R&D) (2003–2013). NTD definitions have been developed to a higher precision since the early 2000s, with the following main features: NTDs are characterised as a) poverty related, b) endemic to the tropics and subtropics, c) lacking public health attention, d) having poor research funding and shortcomings in R&D, e) usually associated with high morbidity but low mortality, and f) often having no specific treatment available. Dengue meets most of these criteria, but not all. Although dengue predominantly affects resource-limited countries, it does not necessarily only target the poor and marginalised in those countries. Dengue increasingly attracts public health attention, and in some affected countries it is now a high profile disease. Research funding for dengue has increased exponentially in the past two decades, in particular in the area of dengue vaccine development. However, despite advances in dengue research, dengue epidemics are increasing in frequency and magnitude, and dengue is expanding to new areas. Specific treatment and a highly effective vaccine remain elusive. Major research gaps exist in the area of integrated surveillance and vector control. Hence, although dengue differs from many of the NTDs, it still meets important criteria commonly used for NTDs. The current need for increased R&D spending, shared by dengue and other NTDs, is perhaps the key reason why dengue should continue to be considered an NTD.
AB - Dengue is currently listed as a “neglected tropical disease” (NTD). But is dengue still an NTD or not? Classifying dengue as an NTD may carry advantages, but is it justified? This review considers the criteria for the definition of an NTD, the current diverse lists of NTDs by different stakeholders, and the commonalities and differences of dengue with other NTDs. We also review the current research gaps and research activities and the adequacy of funding for dengue research and development (R&D) (2003–2013). NTD definitions have been developed to a higher precision since the early 2000s, with the following main features: NTDs are characterised as a) poverty related, b) endemic to the tropics and subtropics, c) lacking public health attention, d) having poor research funding and shortcomings in R&D, e) usually associated with high morbidity but low mortality, and f) often having no specific treatment available. Dengue meets most of these criteria, but not all. Although dengue predominantly affects resource-limited countries, it does not necessarily only target the poor and marginalised in those countries. Dengue increasingly attracts public health attention, and in some affected countries it is now a high profile disease. Research funding for dengue has increased exponentially in the past two decades, in particular in the area of dengue vaccine development. However, despite advances in dengue research, dengue epidemics are increasing in frequency and magnitude, and dengue is expanding to new areas. Specific treatment and a highly effective vaccine remain elusive. Major research gaps exist in the area of integrated surveillance and vector control. Hence, although dengue differs from many of the NTDs, it still meets important criteria commonly used for NTDs. The current need for increased R&D spending, shared by dengue and other NTDs, is perhaps the key reason why dengue should continue to be considered an NTD.
UR - http://www.scopus.com/inward/record.url?scp=84929469839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929469839&partnerID=8YFLogxK
U2 - 10.1371/journal.pntd.0003632
DO - 10.1371/journal.pntd.0003632
M3 - Article
C2 - 25928673
AN - SCOPUS:84929469839
SN - 1935-2727
VL - 9
JO - PLoS neglected tropical diseases
JF - PLoS neglected tropical diseases
IS - 4
M1 - e0003632
ER -